IL127771A0 - Non-aqueous polar aprotic peptide formualtions - Google Patents

Non-aqueous polar aprotic peptide formualtions

Info

Publication number
IL127771A0
IL127771A0 IL12777197A IL12777197A IL127771A0 IL 127771 A0 IL127771 A0 IL 127771A0 IL 12777197 A IL12777197 A IL 12777197A IL 12777197 A IL12777197 A IL 12777197A IL 127771 A0 IL127771 A0 IL 127771A0
Authority
IL
Israel
Prior art keywords
formualtions
polar aprotic
aqueous polar
peptide
aprotic peptide
Prior art date
Application number
IL12777197A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21810971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127771(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL127771A0 publication Critical patent/IL127771A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL12777197A 1996-07-03 1997-07-01 Non-aqueous polar aprotic peptide formualtions IL127771A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2269996P 1996-07-03 1996-07-03
PCT/US1997/011450 WO1998000158A1 (en) 1996-07-03 1997-07-01 Non-aqueous polar aprotic peptide formulations

Publications (1)

Publication Number Publication Date
IL127771A0 true IL127771A0 (en) 1999-10-28

Family

ID=21810971

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12777197A IL127771A0 (en) 1996-07-03 1997-07-01 Non-aqueous polar aprotic peptide formualtions
IL170958A IL170958A (en) 1996-07-03 2005-09-19 Stable non-proteinaceous polar aphrotic preparations of peptides
IL178824A IL178824A (en) 1996-07-03 2006-10-23 Stable peptide non-aqueous polar erotic preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL170958A IL170958A (en) 1996-07-03 2005-09-19 Stable non-proteinaceous polar aphrotic preparations of peptides
IL178824A IL178824A (en) 1996-07-03 2006-10-23 Stable peptide non-aqueous polar erotic preparation

Country Status (29)

Country Link
US (3) US5932547A (xx)
EP (2) EP0921808B1 (xx)
JP (2) JP2000515131A (xx)
CN (4) CN102512658A (xx)
AR (1) AR007714A1 (xx)
AT (2) ATE224199T1 (xx)
AU (1) AU739169B2 (xx)
BR (1) BR9710132A (xx)
CA (1) CA2259557A1 (xx)
CO (1) CO4870762A1 (xx)
CY (1) CY2486B1 (xx)
CZ (2) CZ300378B6 (xx)
DE (2) DE69728582T2 (xx)
DK (2) DK0921808T3 (xx)
ES (2) ES2181010T3 (xx)
HU (1) HUP9904270A3 (xx)
ID (2) ID28822A (xx)
IL (3) IL127771A0 (xx)
MY (1) MY128850A (xx)
NO (2) NO322514B1 (xx)
NZ (1) NZ333294A (xx)
PL (1) PL189015B1 (xx)
PT (2) PT1208846E (xx)
RO (1) RO119863B1 (xx)
RU (1) RU2203084C2 (xx)
SK (1) SK283926B6 (xx)
TW (1) TW584562B (xx)
WO (1) WO1998000158A1 (xx)
ZA (1) ZA975941B (xx)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1274459B1 (en) 2000-04-19 2005-11-16 Genentech, Inc. Sustained release formulations comprising growth hormone
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DK1372729T3 (da) * 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
US7318931B2 (en) * 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
WO2003068805A2 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
CA2489325C (en) * 2002-06-17 2010-08-10 Alza Corporation Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006512370A (ja) * 2002-12-19 2006-04-13 アルザ・コーポレーション 安定な非水性単相ゲル、および植込み型デバイスから送達するためのその配合物
US8110209B2 (en) * 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006521897A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
MXPA05010604A (es) * 2003-03-31 2005-11-23 Alza Corp Sistema de administracion osmotica y metodo para disminuir los tiempos de arranque para sistemas de administracion osmotica.
EP1638522B1 (en) * 2003-04-25 2011-01-12 Boston Scientific Scimed, Inc. Solid drug formulation and device for storage and controlled delivery thereof
WO2005000222A2 (en) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
RU2006118808A (ru) * 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Осмотический насос с самоудерживающейся, выполненной с возможностью быстрого пуска мембранной пробкой
RU2006119632A (ru) * 2003-11-06 2007-12-20 Алза Корпорейшн (Us) Модульный ограничитель скорости впитывания для использования с имплантируемым осмотическим насосом
FI116942B (fi) * 2004-05-10 2006-04-13 Biohit Oyj Proteiini- ja peptidistabilointi
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP2361630A1 (en) * 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantable drug delivery device comprising particles and an osmotic pump
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP1962586B1 (en) * 2005-12-22 2017-07-12 Oakwood Laboratories L.L.C. Sublimable sustained release delivery system and method of making same
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2007284759B2 (en) * 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
JP2010539057A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのヒト膵臓ポリペプチドの使用
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR20110007242A (ko) * 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
RS60101B1 (sr) 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
NZ592113A (en) * 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
JP2013501071A (ja) 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド リナクロチドを含む処方物
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
EA201290799A1 (ru) 2010-02-17 2013-03-29 Айронвуд Фармасьютикалз, Инк. Лечение желудочно-кишечных расстройств
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
LT2603232T (lt) 2010-08-11 2020-01-27 Ironwood Pharmaceuticals, Inc. Stabilios linaklotido vaisto formos
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
BR112013023062B1 (pt) * 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
PL2776055T3 (pl) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych
SG11201401921YA (en) * 2011-10-31 2014-05-29 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes
US9207513B2 (en) 2012-04-10 2015-12-08 The Regents Of The University Of California Nanocrystal-polymer nanocomposite electrochromic device
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
DK3102184T3 (da) * 2014-02-06 2019-05-06 Xeris Pharmaceuticals Inc Stabile formuleringer af peptider og fremgangsmåder til fremstilling
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2975708T3 (es) 2015-01-29 2024-07-12 Novo Nordisk As Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
KR20240036128A (ko) 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL22493A (en) * 1963-12-09 1968-10-24 Crown Zellerbach Corp Membrane penetrant composition containing a dialkyl sulfoxide
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
GB2008403B (en) * 1977-11-04 1982-07-28 Christie R B Parsons J A Pharmaceutical compositions
GB2119248A (en) * 1982-04-28 1983-11-16 John Kenneth Mcmullen Insulin formulations and method of producing them
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
US4851385A (en) * 1987-07-15 1989-07-25 Indiana University Foundation LHRH antagonist analogs having low histamine-release activity
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
WO1994006452A1 (en) * 1992-09-21 1994-03-31 The Upjohn Company Sustained-release protein formulations
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
RU2143889C1 (ru) * 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
PT877599E (pt) * 1996-02-02 2003-08-29 Alza Corp Administracao continua de leuprolido utilizando um sistema implantavel
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations

Also Published As

Publication number Publication date
RU2203084C2 (ru) 2003-04-27
CZ434098A3 (cs) 1999-04-14
NO986207L (no) 1999-03-03
CN102512658A (zh) 2012-06-27
CZ300378B6 (cs) 2009-05-06
SK283926B6 (sk) 2004-05-04
EP0921808B1 (en) 2002-09-18
DE69728582D1 (de) 2004-05-13
NZ333294A (en) 2000-05-26
DE69715639T2 (de) 2003-02-06
CA2259557A1 (en) 1998-01-08
TW584562B (en) 2004-04-21
CY2486B1 (en) 2005-06-03
MY128850A (en) 2007-02-28
DK0921808T3 (da) 2003-01-27
ES2215967T3 (es) 2004-10-16
EP1208846B1 (en) 2004-04-07
ID19718A (id) 1998-07-30
PL330927A1 (en) 1999-06-07
CN101116742A (zh) 2008-02-06
ID28822A (id) 1998-01-08
NO322514B1 (no) 2006-10-16
WO1998000158A1 (en) 1998-01-08
IL178824A0 (en) 2007-03-08
HUP9904270A3 (en) 2001-08-28
RO119863B1 (ro) 2005-05-30
SK179798A3 (en) 1999-05-07
CO4870762A1 (es) 1999-12-27
CZ299464B6 (cs) 2008-08-06
ATE263570T1 (de) 2004-04-15
BR9710132A (pt) 1999-08-10
NO986207D0 (no) 1998-12-30
JP2000515131A (ja) 2000-11-14
AU3587997A (en) 1998-01-21
EP0921808A1 (en) 1999-06-16
ATE224199T1 (de) 2002-10-15
PT921808E (pt) 2003-01-31
AU739169B2 (en) 2001-10-04
US6235712B1 (en) 2001-05-22
US6124261A (en) 2000-09-26
DE69728582T2 (de) 2004-08-19
CN101239179A (zh) 2008-08-13
DK1208846T3 (da) 2004-08-02
US5932547A (en) 1999-08-03
HUP9904270A2 (hu) 2000-05-28
PT1208846E (pt) 2004-06-30
NO20063870L (no) 1999-03-03
ZA975941B (en) 1998-04-16
JP2009073852A (ja) 2009-04-09
IL170958A (en) 2009-11-18
IL178824A (en) 2011-08-31
ES2181010T3 (es) 2003-02-16
CN1636589A (zh) 2005-07-13
EP1208846A2 (en) 2002-05-29
AR007714A1 (es) 1999-11-10
DE69715639D1 (de) 2002-10-24
PL189015B1 (pl) 2005-06-30
EP1208846A3 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
IL127771A0 (en) Non-aqueous polar aprotic peptide formualtions
PL330869A1 (en) Non-aqueous protical peptide preparations
HK1036997A1 (en) Peptides
EP0948832A4 (en) TERMINAL BOARD
GB0127669D0 (en) Polypeptide
GB9825854D0 (en) Peptide
GB2311696B (en) Terminal equipment
GB9812675D0 (en) Peptides
TW441779U (en) Ice making apparatus
GB9613046D0 (en) Making an electrical joint
EP1141267A4 (en) ELIMINATED PROTEINS
TW379845U (en) Multipole changeover disconnector
GB9807890D0 (en) Peptides
GB2311177B (en) Residual current devices
GB2339313B (en) Terminal
GB0224538D0 (en) Polypeptide
GB9814672D0 (en) Protein secretion
GB9819387D0 (en) Polypeptide
AU132253S (en) Terminal
GB9603624D0 (en) Switch connector
TW336588U (en) Current connector
GB9818368D0 (en) Vitronectin-derived peptides
GB9827603D0 (en) Peptides
GB9800321D0 (en) Peptides
TW350297U (en) Electric roaster

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees